Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study

AIMS/HYPOTHESIS: Type 2 diabetes, particularly with concomitant CVD, is associated with an increased risk of cognitive impairment. We assessed the effect on accelerated cognitive decline (ACD) of the DPP-4 inhibitor linagliptin vs the sulfonylurea glimepiride in individuals with type 2 diabetes. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Biessels, Geert Jan, Verhagen, Chloë, Janssen, Jolien, van den Berg, Esther, Wallenstein, Gudrun, Zinman, Bernard, Espeland, Mark A., Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099814/
https://www.ncbi.nlm.nih.gov/pubmed/33559704
http://dx.doi.org/10.1007/s00125-021-05393-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099814/
https://www.ncbi.nlm.nih.gov/pubmed/33559704
http://dx.doi.org/10.1007/s00125-021-05393-8

Ejemplares similares